Harrell W Chesson1, Lauri E Markowitz1, Susan Hariri1, Donatus U Ekwueme2, Mona Saraiya2. 1. a Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention , Atlanta , GA , USA. 2. b Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Abstract
INTRODUCTION: The objective of this study was to assess the incremental costs and benefits of the 9-valent HPV vaccine (9vHPV) compared with the quadrivalent HPV vaccine (4vHPV). Like 4vHPV, 9vHPV protects against HPV types 6, 11, 16, and 18. 9vHPV also protects against 5 additional HPV types 31, 33, 45, 52, and 58. METHODS: We adapted a previously published model of the impact and cost-effectiveness of 4vHPV to include the 5 additional HPV types in 9vHPV. The vaccine strategies we examined were (1) 4vHPV for males and females; (2) 9vHPV for females and 4vHPV for males; and (3) 9vHPV for males and females. In the base case, 9vHPV cost $13 more per dose than 4vHPV, based on available vaccine price information. RESULTS: Providing 9vHPV to females compared with 4vHPV for females (assuming 4vHPV for males in both scenarios) was cost-saving regardless of whether or not cross-protection for 4vHPV was assumed. The cost per quality-adjusted life year (QALY) gained by 9vHPV for both sexes (compared with 4vHPV for both sexes) was < $0 (cost-saving) when assuming no cross-protection for 4vHPV and $8,600 when assuming cross-protection for 4vHPV. CONCLUSIONS: Compared with a vaccination program of 4vHPV for both sexes, a vaccination program of 9vHPV for both sexes can improve health outcomes and can be cost-saving.
INTRODUCTION: The objective of this study was to assess the incremental costs and benefits of the 9-valent HPV vaccine (9vHPV) compared with the quadrivalent HPV vaccine (4vHPV). Like 4vHPV, 9vHPV protects against HPV types 6, 11, 16, and 18. 9vHPV also protects against 5 additional HPV types 31, 33, 45, 52, and 58. METHODS: We adapted a previously published model of the impact and cost-effectiveness of 4vHPV to include the 5 additional HPV types in 9vHPV. The vaccine strategies we examined were (1) 4vHPV for males and females; (2) 9vHPV for females and 4vHPV for males; and (3) 9vHPV for males and females. In the base case, 9vHPV cost $13 more per dose than 4vHPV, based on available vaccine price information. RESULTS: Providing 9vHPV to females compared with 4vHPV for females (assuming 4vHPV for males in both scenarios) was cost-saving regardless of whether or not cross-protection for 4vHPV was assumed. The cost per quality-adjusted life year (QALY) gained by 9vHPV for both sexes (compared with 4vHPV for both sexes) was < $0 (cost-saving) when assuming no cross-protection for 4vHPV and $8,600 when assuming cross-protection for 4vHPV. CONCLUSIONS: Compared with a vaccination program of 4vHPV for both sexes, a vaccination program of 9vHPV for both sexes can improve health outcomes and can be cost-saving.
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Elmar A Joura; Anna R Giuliano; Ole-Erik Iversen; Celine Bouchard; Constance Mao; Jesper Mehlsen; Edson D Moreira; Yuen Ngan; Lone Kjeld Petersen; Eduardo Lazcano-Ponce; Punnee Pitisuttithum; Jaime Alberto Restrepo; Gavin Stuart; Linn Woelber; Yuh Cheng Yang; Jack Cuzick; Suzanne M Garland; Warner Huh; Susanne K Kjaer; Oliver M Bautista; Ivan S F Chan; Joshua Chen; Richard Gesser; Erin Moeller; Michael Ritter; Scott Vuocolo; Alain Luxembourg Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Susan Hariri; Elizabeth R Unger; Sean Schafer; Linda M Niccolai; Ina U Park; Karen C Bloch; Nancy M Bennett; Martin Steinau; Michelle L Johnson; Lauri E Markowitz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-21 Impact factor: 4.254
Authors: Harrell W Chesson; Donatus U Ekwueme; Mona Saraiya; Meg Watson; Douglas R Lowy; Lauri E Markowitz Journal: Vaccine Date: 2012-08-04 Impact factor: 3.641
Authors: Suzanne E Powell; Susan Hariri; Martin Steinau; Heidi M Bauer; Nancy M Bennett; Karen C Bloch; Linda M Niccolai; Sean Schafer; Elizabeth R Unger; Lauri E Markowitz Journal: Vaccine Date: 2012-11-06 Impact factor: 3.641
Authors: Eleonore B Baughan; Erin M Keizur; Christopher A Damico; Elizabeth Mayfield Arnold; Jamie S Ko; Jeffrey D Klausner Journal: Sex Transm Dis Date: 2019-08 Impact factor: 2.830
Authors: Carmen H Logie; Ashley Lacombe-Duncan; Philip Baiden; Peter A Newman; Suchon Tepjan; Clara Rubincam; Nick Doukas; Farid Asey Journal: BMJ Open Date: 2018-04-20 Impact factor: 2.692
Authors: S M Garland; P Pitisuttithum; H Y S Ngan; C-H Cho; C-Y Lee; C-A Chen; Y C Yang; T-Y Chu; N-F Twu; R Samakoses; Y Takeuchi; T H Cheung; S C Kim; L-M Huang; B-G Kim; Y-T Kim; K-H Kim; Y-S Song; S Lalwani; J-H Kang; M Sakamoto; H-S Ryu; N Bhatla; H Yoshikawa; M C Ellison; S R Han; E Moeller; S Murata; M Ritter; M Sawata; C Shields; A Walia; G Perez; A Luxembourg Journal: J Infect Dis Date: 2018-06-05 Impact factor: 5.226